Literature DB >> 1359323

Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies?

K Ariyoshi1, E Harwood, R Chiengsong-Popov, J Weber.   

Abstract

The mechanism of clearance of human immunodeficiency virus-1 (HIV-1) viraemia is not fully understood. In two patients with acute HIV-1 infection, initial high titres of free infectious virus in plasma declined rapidly to undetectable levels within 4-8 weeks, an event that was coincident with seroconversion. Neutralising antibodies directed against the first autologous isolates taken during the viraemic periods could not be detected in either patient around the time of disappearance of plasma virus. In the absence of functional neutralising antibody, it is unlikely that humoral factors are responsible for the suppression of primary viraemia in early HIV infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359323     DOI: 10.1016/0140-6736(92)92953-d

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

1.  Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12.

Authors:  M B Zwick; L L Bonnycastle; A Menendez; M B Irving; C F Barbas; P W Parren; D R Burton; J K Scott
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.

Authors:  J Weber; E M Fenyö; S Beddows; P Kaleebu; A Björndal
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors:  J P Moore; Y Cao; D D Ho; R A Koup
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

4.  Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.

Authors:  Todd Bradley; Daniela Fera; Jinal Bhiman; Leila Eslamizar; Xiaozhi Lu; Kara Anasti; Ruijung Zhang; Laura L Sutherland; Richard M Scearce; Cindy M Bowman; Christina Stolarchuk; Krissey E Lloyd; Robert Parks; Amanda Eaton; Andrew Foulger; Xiaoyan Nie; Salim S Abdool Karim; Susan Barnett; Garnett Kelsoe; Thomas B Kepler; S Munir Alam; David C Montefiori; M Anthony Moody; Hua-Xin Liao; Lynn Morris; Sampa Santra; Stephen C Harrison; Barton F Haynes
Journal:  Cell Rep       Date:  2015-12-24       Impact factor: 9.423

5.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.

Authors:  Natalia T Freund; Haoqing Wang; Louise Scharf; Lilian Nogueira; Joshua A Horwitz; Yotam Bar-On; Jovana Golijanin; Stuart A Sievers; Devin Sok; Hui Cai; Julio C Cesar Lorenzi; Ariel Halper-Stromberg; Ildiko Toth; Alicja Piechocka-Trocha; Harry B Gristick; Marit J van Gils; Rogier W Sanders; Lai-Xi Wang; Michael S Seaman; Dennis R Burton; Anna Gazumyan; Bruce D Walker; Anthony P West; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Sci Transl Med       Date:  2017-01-18       Impact factor: 17.956

6.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

7.  Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.

Authors:  Hongtao Zhang; Yujun Huang; Raja Fayad; Gregory T Spear; Liang Qiao
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Interlaboratory variability of CD8 subset measurements by flow cytometry and its applications to multicenter clinical trials. NAID/NICHD Women and Infants Transmission Study Group.

Authors:  A L Landay; D Brambilla; J Pitt; G Hillyer; D Golenbock; J Moye; S Landesman; J Kagan
Journal:  Clin Diagn Lab Immunol       Date:  1995-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.